Touted as the "latest in the medical saga that started 15 years ago when testosterone which for decades had been used mainly in rare clinical circumstances, increasingly is prescribed for middle-aged and older men whose testosterone levels decline" MedPageToday "reports" http://www.medpagetoday.com/Endocrinology/GeneralEndocrinology/56255
The specter of TRT-related cardiovascular disease, blood clots and prostate cancer are once again raised.
Preliminary study results addressing thus far only the benefits libido and "vitality" among elderly obese white men are published here: http://www.nejm.org/doi/full/10.1056/NEJMoa1506119
The study participants were elderly obese symptomatic white men averaging 72 years included no one younger than 65. Only subjective benefits of "vitality" and only using Androgel for 12 months are reviewed at this point..
"Four more arms of the trial (cognitive function, anemia, bone density, and cardiovascular health) won't likely be published until late 2016 or 2017"
The rush to judgement:
"it does not make me feel comfortable recommending this medication for routine use in otherwise healthy men," "I would not be inclined to prescribe this medication."
James Stein, MD, professor of cardiovascular medicine, University of Wisconsin School of Medicine and Public Health
"Concerns about increased risk of prostate cancer, blood clots, and cardiovascular problems have been raised about testosterone"
""Millions of men take testosterone, hoping for a fountain of youth,"
"This therapy is too risky for widespread use"
Steven Nissen, MD, chairman of cardiovascular medicine, Cleveland Clinic Foundation.
"Therapy was not a panacea and the findings alone might be insufficient to support a decision to initiate testosterone therapy in symptomatic older men," wrote Eric Orwoll, MD, physician, Oregon Health and Science University.
The specter of TRT-related cardiovascular disease, blood clots and prostate cancer are once again raised.
Preliminary study results addressing thus far only the benefits libido and "vitality" among elderly obese white men are published here: http://www.nejm.org/doi/full/10.1056/NEJMoa1506119
The study participants were elderly obese symptomatic white men averaging 72 years included no one younger than 65. Only subjective benefits of "vitality" and only using Androgel for 12 months are reviewed at this point..
"Four more arms of the trial (cognitive function, anemia, bone density, and cardiovascular health) won't likely be published until late 2016 or 2017"
The rush to judgement:
"it does not make me feel comfortable recommending this medication for routine use in otherwise healthy men," "I would not be inclined to prescribe this medication."
James Stein, MD, professor of cardiovascular medicine, University of Wisconsin School of Medicine and Public Health
"Concerns about increased risk of prostate cancer, blood clots, and cardiovascular problems have been raised about testosterone"
""Millions of men take testosterone, hoping for a fountain of youth,"
"This therapy is too risky for widespread use"
Steven Nissen, MD, chairman of cardiovascular medicine, Cleveland Clinic Foundation.
"Therapy was not a panacea and the findings alone might be insufficient to support a decision to initiate testosterone therapy in symptomatic older men," wrote Eric Orwoll, MD, physician, Oregon Health and Science University.
